Syntax Bio, a synthetic biology company programming the next generation of cell therapies, has published new research in ...

For years, Yale researchers David Breslow and Mustafa Khokha have worked together with a similar challenge in their ...

Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of new research in Science Advances detailing the company’s CRISPR-based ...

CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the best short squeeze stocks to buy right now. Citizens reaffirmed its ...

In a groundbreaking fusion of artificial intelligence and gene editing, researchers are leveraging machine learning to enhance CRISPR technology’s precision and efficiency. This integration is opening ...

You've probably heard about the gene-editing technology CRISPR. The massive biotech breakthrough, which has emerged in the last decade, has mainly been touted for the ways it will let scientists edit ...

Stanford researchers and their collaborators have revealed a new device that could change the way scientists conduct gene-editing experiments. The device, CRISPR-GPT, is an artificial intelligence lab ...

Thinking about whether CRISPR Therapeutics stock is truly a bargain or just the next biotech craze? Let’s break down its value case together. After a sharp rally earlier this year, the stock is still ...

Higher yields, greater resilience to climatic changes or diseases—the demands on crop plants are constantly growing. To ...

The new GE technology — for which the Indian Council of Agricultural Research (ICAR) has recently been granted a patent — deploys the so-called TnpB or Transposon-associated proteins.